Document is current
Any future updates will be listed below
-
Authors
Frishberg, Amit
Milman, Neta
Alpert, Ayelet
Spitzer, Hannah https://orcid.org/0000-0002-7858-0936
Asani, Ben https://orcid.org/0000-0003-4809-2859
Schiefelbein, Johannes B.
Bakin, Evgeny
Regev-Berman, Karen
Priglinger, Siegfried G.
Schultze, Joachim L. https://orcid.org/0000-0003-2812-9853
Theis, Fabian J. https://orcid.org/0000-0002-2419-1943
Shen-Orr, Shai S. https://orcid.org/0000-0002-6991-7736
-
Funding
Funding for this research was provided by:
ISRAEL SCIENCE FOUNDATION
- License Information
-
More Information
Article History
Received: 18 January 2023
Accepted: 9 October 2023
First Online: 27 October 2023
Competing interests
: S.S.O. holds equity and is a consultant of CytoReason. A.F., E.B., and K.R.B. are employees and hold equity in CytoReason. F.J.T. reports receiving consulting fees from ImmunAI and CytoReason and ownership interest in Dermagnostix. S.P. receives speaker and consultant honoraria from and has served on advisory boards for Abbott, Alcon, Geuder, Oculus, Schwind, STAAR, TearLab, Thieme Compliance, Ziemer, Zeiss and research funding from Abbott, Alcon, Hoya, Oculentis, Oculus, Schwind and Zeiss. The remaining authors declare no competing interests.
